Trials / Unknown
UnknownNCT05675748
Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients
A Non-interventional Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients With Mild/Normal COVID-19
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients. The primary outcome measure was the proportion of patients with severe/critical illness within 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azvudine | Azvudine tablets are taken orally 5mg daily for a maximum of 14 days |
Timeline
- Start date
- 2023-01-15
- Primary completion
- 2023-03-15
- Completion
- 2023-04-15
- First posted
- 2023-01-09
- Last updated
- 2023-01-13
Source: ClinicalTrials.gov record NCT05675748. Inclusion in this directory is not an endorsement.